

Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences

September 6, 2022 at 4:01 PM EDT

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- [Fulcrum Therapeutics, Inc.](#) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:

- **H.C. Wainwright 24th Annual Global Investment Conference**
Tuesday, September 13, 2022
- **Morgan Stanley 20th Annual Global Healthcare Conference**
Wednesday, September 14, 2022 at 10:00 a.m. ET (Fireside Chat)

A live audio webcast of the Morgan Stanley fireside chat will be available through the Investor Relations section of the Fulcrum website at <https://ir.fulcrumtx.com/events-and-presentations>. An archived replay will be available on the Company's website for 30 days.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum's two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, please visit www.fulcrumtx.com.

Contacts:

Investors

Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

Media

Dee Smith
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
dsmith@fulcrumtx.com
202-746-1324